NewAmsterdam Pharma Net Income
| NAMS Stock | 34.63 0.23 0.66% |
As of the 14th of February 2026, NewAmsterdam Pharma secures the Risk Adjusted Performance of (0.03), mean deviation of 2.31, and Standard Deviation of 2.88. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewAmsterdam Pharma, as well as the relationship between them. Please verify NewAmsterdam Pharma market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if NewAmsterdam Pharma is priced some-what accurately, providing market reflects its recent price of 34.63 per share. Given that NewAmsterdam Pharma has information ratio of (0.07), we recommend you to check NewAmsterdam Pharma's last-minute market performance to make sure the company can sustain itself at a future point.
NewAmsterdam Pharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 91.6091 | Revenue | Earnings Share (2.04) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -217.4 M | -206.6 M | |
| Net Loss | -25.7 M | -27 M | |
| Net Loss | -217.4 M | -206.6 M | |
| Net Loss | (2.94) | (3.09) | |
| Net Income Per E B T | 1.15 | 1.10 |
NewAmsterdam | Net Income | Build AI portfolio with NewAmsterdam Stock |
The evolution of Net Income for NewAmsterdam Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NewAmsterdam Pharma compares to historical norms and industry peers.
Latest NewAmsterdam Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of NewAmsterdam Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in NewAmsterdam Pharma financial statement analysis. It represents the amount of money remaining after all of NewAmsterdam Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is NewAmsterdam Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (241.6 M) | 10 Years Trend |
|
Net Income |
| Timeline |
NewAmsterdam Net Income Regression Statistics
| Arithmetic Mean | (57,894,772) | |
| Coefficient Of Variation | (152.94) | |
| Mean Deviation | 71,877,695 | |
| Median | (7,022,966) | |
| Standard Deviation | 88,545,697 | |
| Sample Variance | 7840.3T | |
| Range | 234.6M | |
| R-Value | (0.77) | |
| Mean Square Error | 3432.8T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (13,463,245) | |
| Total Sum of Squares | 125445.4T |
NewAmsterdam Net Income History
Other Fundumenentals of NewAmsterdam Pharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
NewAmsterdam Pharma Net Income component correlations
NewAmsterdam Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Net Income. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will NewAmsterdam introduce new products? Factors like these will boost the valuation of NewAmsterdam Pharma. Anticipated expansion of NewAmsterdam directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
NewAmsterdam Pharma's market price often diverges from its book value, the accounting figure shown on NewAmsterdam's balance sheet. Smart investors calculate NewAmsterdam Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since NewAmsterdam Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between NewAmsterdam Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewAmsterdam Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NewAmsterdam Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NewAmsterdam Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NewAmsterdam Pharma.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in NewAmsterdam Pharma on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding NewAmsterdam Pharma or generate 0.0% return on investment in NewAmsterdam Pharma over 90 days. NewAmsterdam Pharma is related to or competes with Kymera Therapeutics, Viking Therapeutics, Immunovant, Crinetics Pharmaceuticals, Arcellx, Praxis Precision, and Ligand Pharmaceuticals. NewAmsterdam Pharma is entity of United States More
NewAmsterdam Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NewAmsterdam Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NewAmsterdam Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 12.63 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 4.5 |
NewAmsterdam Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NewAmsterdam Pharma's standard deviation. In reality, there are many statistical measures that can use NewAmsterdam Pharma historical prices to predict the future NewAmsterdam Pharma's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.20) |
NewAmsterdam Pharma February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.31 | |||
| Coefficient Of Variation | (2,093) | |||
| Standard Deviation | 2.88 | |||
| Variance | 8.31 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 12.63 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 4.5 | |||
| Skewness | (0.05) | |||
| Kurtosis | (0.19) |
NewAmsterdam Pharma Backtested Returns
NewAmsterdam Pharma has Sharpe Ratio of -0.0494, which conveys that the firm had a -0.0494 % return per unit of risk over the last 3 months. NewAmsterdam Pharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify NewAmsterdam Pharma's Mean Deviation of 2.31, risk adjusted performance of (0.03), and Standard Deviation of 2.88 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.76, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NewAmsterdam Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NewAmsterdam Pharma is expected to be smaller as well. At this point, NewAmsterdam Pharma has a negative expected return of -0.14%. Please make sure to verify NewAmsterdam Pharma's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.11 |
Insignificant predictability
NewAmsterdam Pharma has insignificant predictability. Overlapping area represents the amount of predictability between NewAmsterdam Pharma time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NewAmsterdam Pharma price movement. The serial correlation of 0.11 indicates that less than 11.0% of current NewAmsterdam Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 1.92 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NewAmsterdam Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, NewAmsterdam Pharma reported net income of (241.6 Million). This is 170.79% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 142.31% higher than that of the company.
NewAmsterdam Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in net income category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in NewAmsterdam Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of NewAmsterdam Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NewAmsterdam Pharma's value.| Shares | Alliancebernstein L.p. | 2025-06-30 | 2.3 M | Cormorant Asset Management, Llc | 2025-06-30 | 2.2 M | Capital Research & Mgmt Co - Division 3 | 2025-06-30 | 2.1 M | Hhg Plc | 2025-06-30 | 2 M | Fmr Inc | 2025-06-30 | 1.9 M | Woodline Partners Lp | 2025-06-30 | 1.9 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.8 M | Maverick Capital Ltd | 2025-06-30 | 1.5 M | Jpmorgan Chase & Co | 2025-06-30 | 1.5 M | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 10.7 M | Fcpm Iii Services Bv | 2025-06-30 | 10.6 M |
NewAmsterdam Fundamentals
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (158.46) % | ||||
| Current Valuation | 3.23 B | ||||
| Shares Outstanding | 113.39 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 99.54 % | ||||
| Number Of Shares Shorted | 7.1 M | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 111.42 X | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 35.24 M | ||||
| EBITDA | (241.49 M) | ||||
| Net Income | (241.6 M) | ||||
| Total Debt | 448 K | ||||
| Book Value Per Share | 6.43 X | ||||
| Cash Flow From Operations | (158.56 M) | ||||
| Short Ratio | 9.89 X | ||||
| Earnings Per Share | (2.04) X | ||||
| Target Price | 48.96 | ||||
| Number Of Employees | 68 | ||||
| Beta | 0.069 | ||||
| Market Capitalization | 3.93 B | ||||
| Total Asset | 864.62 M | ||||
| Retained Earnings | (558.57 M) | ||||
| Working Capital | 756.5 M | ||||
| Net Asset | 864.62 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.